🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06836531
Enrolling by invitation Observational

POCT Detection for Blood Concentration of Tirofiban in Acute Myocardial Infarction Based on Azo-POP Probe.

NCT06836531 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital of Ningbo University
Phase
Observational
Started
2025-03-30
Last updated
2025-03-25

Condition(s) studied

Acute Myocardial Infarction (AMI)

Study summary

The goal of this observational study is to monitor blood drug concentration during the use of tirofiban, predict the occurrence of intraoperative and postoperative complications related to interventional therapy, and evaluate the efficacy of multiple antiplatelet drugs.The main question it aims to answer is:

1. If the POCT detection technology for blood concentration of tirofiban based on portable mass spectrometer can be used for on-site sampling, clinical testing, and immediate analysis next to patients undergoing coronary intervention therapy.
2. LC-MS/MS untargeted metabolomics analysis techniques combined with machine learning algorithms will be used to screen biomarkers for myocardial infarction.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * The patient meets the diagnostic criteria for STEMI (refer to the "Diagnosis and Treatment Guidelines for Acute ST Segment Elevation Myocardial Infarction (2019)") * The onset time is less than 12 hours * Agree to perform direct PCI * Heart function (Killip class) ≤ Level III * There are no direct PCI contraindications. Exclusion Criteria: * Patients allergic to tirofiban or/and aspirin * Patients with a history of intracranial hemorrhage * Patients with stroke/transient ischemic attack within six months * Patients who have taken oral anticoagulants within 30 days before admission and cannot stop taking them * Patients receiving clopidogrel or ticagrelor from other manufacturers or formulations due to directive events * Patients who have received or plan to undergo fibrinolysis therapy within 24 hours * Patients with a history of major surgery within 30 days, or those who plan to undergo major surgery during the study process * Patients with a history of gastrointestinal bleeding within 6 months, or those with severe bleeding disorders or tendencies towards bleeding * Patients with severe combined liver and kidney dysfunction * Refuse to participate in this experiment.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
First Affiliated Hospital of Ningbo University Ningbo Zhejiang

More First Affiliated Hospital of Ningbo University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06836531 on ClinicalTrials.gov ↗ ← All trials in China